Inhibikase (IKT) director Dennis Berman granted options for 155,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Inhibikase Therapeutics director Dennis N. Berman received a stock option grant covering 155,000 shares of common stock. The option has an exercise price of $1.91 per share and expires on June 26, 2036.
The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service as a director through that date. After this grant, Berman holds stock options for 155,000 underlying shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
BERMAN DENNIS N
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 155,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 155,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 155,000 shares
Exercise price: $1.91 per share
Expiration date: June 26, 2036
+3 more
6 metrics
Option grant size
155,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$1.91 per share
Conversion or exercise price of granted options
Expiration date
June 26, 2036
Option term end date
Vesting date
June 26, 2027
Latest possible vesting date, subject to earlier meeting-based vesting
Total options after grant
155,000 shares
Total option-based holdings following this transaction
Transaction date
June 26, 2026
Date of stock option grant
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.9100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-26T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"the day prior to the next annual meeting of stockholders"
vesting financial
"The options will vest on the earlier of June 26, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Inhibikase Therapeutics (IKT) director Dennis Berman report on this Form 4?
Dennis N. Berman reported receiving a grant of stock options covering 155,000 shares of Inhibikase Therapeutics common stock. These options were awarded as compensation and are not an open-market purchase or sale of existing shares.
What are the key terms of Dennis Berman’s new Inhibikase (IKT) stock options?
The granted options cover 155,000 shares of common stock with an exercise price of $1.91 per share. They expire on June 26, 2036, giving the director a long-term right to buy shares at that fixed price.
When do Dennis Berman’s Inhibikase (IKT) options vest?
The options vest on the earlier of June 26, 2027 or the day before Inhibikase’s next annual meeting of stockholders. Vesting is conditioned on Berman continuing to serve as a director through the applicable vesting date.
Is this Inhibikase (IKT) Form 4 a stock purchase or sale by Dennis Berman?
No, this Form 4 reflects a grant of stock options as compensation, not a market purchase or sale. Berman did not buy or sell existing shares; he received the right to buy shares later at a $1.91 exercise price.